Last €63.30 EUR
Change Today -0.20 / -0.31%
Volume 140.9K
As of 11:35 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

ucb sa (UCB) Snapshot

Open
€63.50
Previous Close
€63.50
Day High
€64.04
Day Low
€63.11
52 Week High
07/10/14 - €65.27
52 Week Low
07/22/13 - €41.57
Market Cap
12.3B
Average Volume 10 Days
185.9K
EPS TTM
€1.12
Shares Outstanding
194.5M
EX-Date
04/29/14
P/E TM
56.5x
Dividend
€1.04
Dividend Yield
1.64%
Current Stock Chart for UCB SA (UCB)

Related News

No related news articles were found.

ucb sa (UCB) Related Businessweek News

No Related Businessweek News Found

ucb sa (UCB) Details

UCB S.A., a biopharmaceutical company, discovers and develops therapies primarily for central nervous system (CNS) disorders and immunology diseases worldwide. Its CNS products include Vimpat and Keppra for epilepsy, and Neupro for Parkinson’s disease and restless legs syndrome; Nootropil for regulating cerebral functions; and Metadate CD for attention deficit hyperactivity disorder. The company is developing Vimpat, which is under Phase III clinical trials for epilepsy-monotherapy; and brivaracetam for epilepsy-adjunctive therapy, as well as developing Vimpat that has completed Phase II clinical trials for epilepsy-paediatric adjunctive therapy, and epilepsy adjunctive therapy. It is also developing UCB0942, which has completed Phase I clinical trials for refractory epilepsy. The company provides immunology products, such as Cimzia for Crohn's disease and rheumatoid arthritis; Xyzal and Zyrtec for allergies; Tussionex for respiratory disease; and Lortab for pain relief. It is also developing CDP7657 that has completed Phase I clinical trials for systemic lupus erythematosus; and UCB4940, which is under Phase I clinical trial for immunological diseases. The company has a strategic collaboration with Five Prime Therapeutics, Inc. for the discovery of biologics targets and therapeutics in the areas of fibrosis-related inflammatory diseases and CNS disorders; and a strategic partnership with Sanofi for the discovery and development of anti-inflammatory small molecules. UCB S.A. was founded in 1928 and is headquartered in Brussels, Belgium.

8,224 Employees
Last Reported Date: 02/28/14
Founded in 1928

ucb sa (UCB) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: €2.1M
Compensation as of Fiscal Year 2013.

ucb sa (UCB) Key Developments

UCB and Dermira Enter into Strategic Collaboration in Dermatology to Broaden Patient Access to Cimzia (Certolizumab Pegol)

UCB and Dermira Inc. announced that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology. This collaboration aims to broaden patient access to Cimzia and make it available to patients with psoriasis, a chronic autoimmune disorder. Cimzia is not currently approved for the treatment of psoriasis by any regulatory authority. Under the terms of the agreement, UCB grants Dermira an exclusive license to develop certolizumab pegol in psoriasis in the US, Canada and the European Union. Dermira will be responsible for phase 3 development costs and will receive payments of up to $49.5 million on the achievement of development and regulatory milestones. Subject to regulatory approval of Cimzia in psoriasis, Dermira is granted an exclusive commercial license to market Cimzia to dermatologists in the US and Canada. UCB will record the sales and Dermira will receive tiered royalty payments on those product sales which are attributable to dermatologists in the US and Canada and up to $40 million upon the achievement of tiered commercial milestones. In support of the partnership, UCB has made a $5 million equity investment in Dermira and a commitment to invest up to an additional $15 million in future Dermira equity financings.

UCB SA Presents at KBC Securities Credit Conference, Jun-13-2014

UCB SA Presents at KBC Securities Credit Conference, Jun-13-2014 . Venue: Brussels, Belgium. Speakers: Alexandra Deschner, Director IR, Raf Remijsen, Director of Treasury & Corporate Finance.

Biotie Therapies Corp. and UCB SA Announce Resignation of Peter Fellner as Director

Optos plc announced that its Chairman, Dr. Peter Fellner, has resigned as a Director of Biotie Therapies Corp, and as a Director of UCB SA.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UCB:BB €63.30 EUR -0.20

UCB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.109.50 CHF -0.30
Grifols SA €38.27 EUR -0.10
Hospira Inc $50.82 USD -0.24
Mylan Inc/PA $50.20 USD -0.50
Sigma-Aldrich Corp $101.71 USD -0.03
View Industry Companies
 

Industry Analysis

UCB

Industry Average

Valuation UCB Industry Range
Price/Earnings 56.5x
Price/Sales 3.4x
Price/Book 2.4x
Price/Cash Flow 58.9x
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UCB SA, please visit www.ucb.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.